{
  "label": "q_cs03_q09_longitudinal",
  "artifact_type": "question",
  "artifact_id": "sha256:f005bf1c5a17d4d71b648f4e279a1c6b8d6570c1f918b9d0c87f95ab98ae6912",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:f7717f742ab207de4172b6a6cccbd34d4b92f4ef7d31135025c1a0eafc15e02c",
    "sha256:fa62e00fd87f2de4931fca8770be4f6bcc619b69612e4bf2cae09f320ef11928"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:01:44.859892",
  "content": "{\n  \"question_id\": \"cs03_q09_longitudinal\",\n  \"scope_id\": \"clinical_signal_03\",\n  \"checkpoint_after\": 5,\n  \"question_type\": \"longitudinal\",\n  \"prompt\": \"Based on the first five weeks of trial data, are there any safety signals in the lab panels?\",\n  \"ground_truth\": {\n    \"canonical_answer\": \"No. All lab panels are within normal limits across all sites. Hepatic, renal, and hematology markers show no adverse trends. The trial is in the enrollment ramp-up phase.\",\n    \"required_evidence_refs\": [\n      \"clinical_signal_03_ep_003\",\n      \"clinical_signal_03_ep_005\"\n    ],\n    \"key_facts\": []\n  }\n}",
  "metadata": {
    "question_id": "cs03_q09_longitudinal",
    "question_type": "longitudinal",
    "checkpoint_after": 5,
    "scope_id": "clinical_signal_03",
    "layer_name": "questions",
    "layer_level": 3,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "6d7a3608bcf394a04e29af4b1e9a4fe23d5057417c0995c4ec3701dbae39f4b8",
      "components": {
        "transform": "a7d463dc476b419c96a5f454f481b455ca81a8d8ee3904631b7729963317406f",
        "inputs": "9af5c5805c4a781d"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a7d463dc476b419c96a5f454f481b455ca81a8d8ee3904631b7729963317406f",
      "components": {
        "transform_id": "3176c030aaa3a69e",
        "source": "929fe273ac2dab06",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}